Rates of Severe Bleeding Are Low in Patients with MDS and Severe Thrombocytopenia and May be Mitigated By Tranexamic Acid
Bibliographic record
Abstract
Abstract Introduction: While thrombocytopenia is common and affects 29% of patients (pts) with MDS, severe thrombocytopenia (platelets (plt) Prophylactic and therapeutic plt transfusions are commonly administered to prevent bleeding in pts with MDS and severe thrombocytopenia but are inconvenient and associated with risks. Since the inception of the MDS registry in 2006 at our centre, we commonly administer tranexamic acid (TXA, 1-1.5 grams PO BID-TID) to thrombocytopenic pts with MDS to decrease minor mucosal bleeding and the use of plt transfusions for non-severe bleeds. The administration of prophylactic and/or therapeutic plt transfusions is at the discretion of the treating haematologist. Objective: To retrospectively audit the bleeding rates and transfusion requirements of pts with MDS and durable severe thrombocytopenia as related to TXA use, plt transfusions, and disease characteristics. Methods: All pts with MDS with durable severe thrombocytopenia (plt count Results: Of 200 pts with severe thrombocytopenia at any time, 99 had durable severe thrombocytopenia and were included. Demographics are presented in Table 1. The pts were classified as receiving TXA alone (n=28), TXA + PROPH, (n=39), PROPH plts alone (n=19) and untreated (n=13). Median time from diagnosis to start of durable severe thrombocytopenia was 0.9 years (IQR 0.2-2.2), duration was 27 weeks (IQR 16-49), and median plt count was 12x109/L (IQR 9-16). Pts receiving TXA +/- PROPH plts had significantly higher rates of concurrent red blood cell transfusion dependence. With a median follow-up of 0.8 years (95% CI 0.6-1.2), actuarial survival was 0.9 years (95% CI 0.7-1.2). 68% of pts were prescribed TXA at any point with a median time from onset of severe thrombocytopenia of 5 weeks (IQR 0-13) and a median duration of 23 weeks (IQR 12-41). Only 32% and 23% of TXA alone and untreated pts respectively required therapeutic plt transfusions at any point with a median time between transfusions of 2.8 and 4.0 weeks respectively. The median number of plt transfusion events per 4-week period was 0 for TXA alone and untreated pts compared with 2.2 and 3.1 events for TXA + PROPH or PROPH alone (p During the period of severe thrombocytopenia, 82% (81/99) of pts had at least one bleeding event, and 5% (5/99) had a grade 4 bleeding event. There was a significant difference in grade 1 and 2 bleeding rates between groups, with the highest rates in pts on TXA +/- PROPH plts (Table 2). There was no significant difference in grade 3 or 4 bleeding rates between groups. Conclusions: Patients with MDS and durable severe thrombocytopenia at a Canadian tertiary care centre had low rates of major bleeding (5%) compared to what has been previously reported in the literature, but poor overall survival. Seventy-one percent of severely thrombocytopenic pts on TXA or no therapy required no therapeutic platelet transfusions for the duration of study follow-up. The benefit of TXA and/or prophylactic platelet transfusions for the prevention of bleeding would be best evaluated in the context of a randomized controlled trial. Download : Download high-res image (224KB) Download : Download full-size image Disclosures Wells: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Alexion: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Lin: Pfizer: Honoraria; Pfizer: Other: advisory board; CSL Behring, Grifols: Other: unrestricted education grant; Novartis: Research Funding. Buckstein: Celgene: Honoraria, Research Funding; Astex: Honoraria.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".